282 related articles for article (PubMed ID: 7660140)
1. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin.
Callas DD; Hoppensteadt D; Fareed J
Semin Thromb Hemost; 1995; 21(2):177-83. PubMed ID: 7660140
[TBL] [Abstract][Full Text] [Related]
2. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
3. A family of arginal thrombin inhibitors related to efegatran.
Smith GF; Shuman RT; Craft TJ; Gifford DS; Kurz KD; Jones ND; Chirgadze N; Hermann RB; Coffman WJ; Sandusky GE; Roberts E; Jackson CV
Semin Thromb Hemost; 1996; 22(2):173-83. PubMed ID: 8807715
[TBL] [Abstract][Full Text] [Related]
4. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
5. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
6. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
[TBL] [Abstract][Full Text] [Related]
8. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
10. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.
Berry CN; Girardot C; Lecoffre C; Lunven C
Thromb Haemost; 1994 Sep; 72(3):381-6. PubMed ID: 7855788
[TBL] [Abstract][Full Text] [Related]
11. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
Lindhout T; Blezer R; Hemker HC
Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
[TBL] [Abstract][Full Text] [Related]
12. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
[TBL] [Abstract][Full Text] [Related]
13. Direct thrombin inhibitors in cardiovascular disease.
Catella-Lawson F
Coron Artery Dis; 1997 Feb; 8(2):105-11. PubMed ID: 9211051
[TBL] [Abstract][Full Text] [Related]
14. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
15. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Mar; 77(3):498-503. PubMed ID: 9066001
[TBL] [Abstract][Full Text] [Related]
16. A quantitative thrombin time for determining levels of hirudin and Hirulog.
Reid TJ; Alving BM
Thromb Haemost; 1993 Oct; 70(4):608-16. PubMed ID: 8115987
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Cannon CP; Maraganore JM; Loscalzo J; McAllister A; Eddings K; George D; Selwyn AP; Adelman B; Fox I; Braunwald E
Am J Cardiol; 1993 Apr; 71(10):778-82. PubMed ID: 8456753
[TBL] [Abstract][Full Text] [Related]
18. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
19. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
[TBL] [Abstract][Full Text] [Related]
20. The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits.
Lu WF; Mo W; Liu Z; Fu WG; Guo DQ; Wang YQ; Song HY
Thromb Res; 2010 Oct; 126(4):e339-43. PubMed ID: 20483158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
